Logo

CLRB

Cellectar Biosciences, Inc.

CLRB

Cellectar Biosciences, Inc. • NASDAQ
$3.55 ▲ 2.90% (+0.10)
Market Cap $11.33 M
52w High $46.80
52w Low $2.71
Dividend Yield 0%
P/E -0.44
Volume 38.63K
Outstanding Shares 3.19M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.798M ▼ $-4.444M ▲ 0% $-1.41 ▲ $-4.392M ▲
Q2-2025 $0 $6.038M ▼ $-5.448M ▲ 0% $-3.39 ▲ $-5.982M ▲
Q1-2025 $0 $6.401M ▼ $-6.604M ▼ 0% $-4.3 ▼ $-6.345M ▲
Q4-2024 $0 $12.745M ▼ $-2.355M ▲ 0% $-1.534 ▲ $-12.676M ▲
Q3-2024 $0 $13.328M $-14.665M 0% $-11.184 $-13.259M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $12.554M ▲ $14.628M ▲ $5.248M ▼ $9.379M ▲
Q2-2025 $11.041M ▼ $13.695M ▼ $6.228M ▼ $7.467M ▼
Q1-2025 $13.905M ▼ $16.042M ▼ $7.789M ▼ $8.253M ▼
Q4-2024 $23.289M ▼ $25.474M ▼ $11.179M ▼ $14.295M ▼
Q3-2024 $34.263M $37.293M $22.128M $15.165M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.444M ▲ $-4.275M ▲ $0 $5.788M ▲ $1.513M ▲ $-4.275M ▲
Q2-2025 $-5.448M ▲ $-5.116M ▲ $0 $2.251M ▲ $-2.864M ▲ $-5.116M ▲
Q1-2025 $-6.604M ▼ $-9.383M ▲ $0 ▲ $0 $-9.383M ▲ $-9.383M ▲
Q4-2024 $-2.355M ▲ $-10.913M ▼ $-61.286K ▼ $0 ▼ $-10.975M ▼ $-10.975M ▼
Q3-2024 $-14.665M $-9.167M $0 $17.561M $8.394M $-9.167M

Five-Year Company Overview

Income Statement

Income Statement Cellectar is a classic late‑stage, pre‑revenue biotech: it has essentially no product revenue yet, and its income statement is driven almost entirely by R&D and operating expenses. Losses have been steady over the past several years, reflecting ongoing clinical work rather than commercial activity. The size of the reported loss per share looks extreme largely because of repeated reverse stock splits, not because the underlying cash losses suddenly exploded. Overall, the pattern is one of a small, focused research company burning money at a controlled but persistent pace as it pushes its pipeline forward.

Balance Sheet

Balance Sheet The balance sheet is very simple and very small. Assets are largely cash, with little in the way of physical assets or inventories, which is typical for a lean biotech. The company carries no debt, which reduces financial strain but also means it relies heavily on equity and partnership funding. Shareholders’ equity has bounced between positive and slightly negative at times, signaling a thin financial cushion and sensitivity to ongoing losses and capital raises. This is a balance sheet built for a research-stage company, not yet for commercialization.

Cash Flow

Cash Flow Cash flow shows a consistent cash burn from operations, driven by clinical trials, research, and general overhead. There is virtually no spending on long‑term assets, so free cash flow closely tracks operating cash outflows. Management has already restructured to stretch its cash runway into the near future, but unless meaningful partnership income or other non-dilutive funding appears, the business model implies recurring needs for fresh capital. The cash flow profile is exactly what you’d expect from a small biotech: all about funding science, with no offsetting product cash yet.

Competitive Edge

Competitive Edge Cellectar is trying to carve out a niche in oncology rather than compete head‑on with the largest players. Its edge lies in a specialized drug‑delivery platform for targeting cancer cells and in a focus on rare cancers with high unmet need. Regulatory designations and a tight focus on orphan indications help, and its know‑how in radiopharmaceuticals is not trivial to replicate. At the same time, it is a very small player in a crowded and fast‑moving field, heavily dependent on larger partners, clinical data, and regulatory success to translate its scientific advantages into a durable market position.

Innovation and R&D

Innovation and R&D Innovation is the core of the story. The phospholipid drug conjugate platform is designed to selectively deliver radioactive or other payloads directly to cancer cells, aiming for stronger effect with fewer side effects. The lead asset, iopofosine, has shown promise in a rare blood cancer, and next‑generation candidates aim at difficult solid tumors. The company runs a lean, outsourced R&D and manufacturing model, which helps conserve cash but increases reliance on external partners. A strategic review and shift of emphasis toward earlier radiopharmaceutical programs underscore both the scientific ambition and the uncertainty about how best to advance and monetize the pipeline.

Summary

Cellectar is a tiny, research‑driven oncology company with no commercial revenue and a straightforward pattern of ongoing operating losses and cash burn. Its balance sheet is light and mostly cash, with no debt but only a modest equity buffer, making access to future funding and partnerships critical. The scientific story centers on a differentiated drug‑delivery platform and radiopharmaceutical approach, aimed especially at rare cancers where it has regulatory tailwinds and potential pricing power. However, the company’s small scale, repeated reverse splits, dependence on external partners, and ongoing strategic review all highlight high execution and financing risk. The next phase of clinical progress, business development deals, and strategic decisions will largely determine whether its scientific platform can evolve into a sustainable business.

NEWS

November 13, 2025 · 7:20 AM UTC

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

October 14, 2025 · 8:30 AM UTC

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

Read more

September 11, 2025 · 8:05 AM UTC

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

Read more

September 5, 2025 · 8:45 AM UTC

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Read more

September 3, 2025 · 8:05 AM UTC

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

Read more